Formosa Pharmaceuticals

4:30 PM - 4:45 PM, Monday, June 3, 2019 ・ Theater 4
Formosa Laboratories offers full-service Antibody-Drug Conjugate manufacturing from antibody production (through domestic alliance), to in-house toxin-linker CMC services and antibody bioconjugation, and finally through to cytotoxic fill-finish drug product manufacturing. To demonstrate our capabilities, Formosa Laboratories is developing a biosimilar of ado-trastuzumab emtansine (Kadcyla), which is available for co-development or out-licensing. Historically, Formosa Laboratories, Inc. produces APIs and UV-filters in its state-of-the-art facilities near Taipei. Its GMP compliance has been approved by DOH of Taiwan, US FDA, BGV of Germany, EDQM and PMDA of Japan. Formosa’s major API products include Vitamin D derivatives. As a major producer in the world, our UV-filter products include avobenzone and Octinoxate. We also provide custom synthesis service from process development to full commercial production for APIs and other specialty chemicals, with full documentation support.
Company Type:
Company HQ State:
Not Provided.
Company HQ Country:
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
Biosimilar ado-trastuzumab emtansine
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Formosa Pharmaceuticals, Inc